Neutral nucleic acid ligands

• US 9,725,724 B2
• Filed: 05/15/2014
• Issued: 08/08/2017
• Est. Priority Date: 05/16/2013
• Status: Active Grant

• Current Assignee: Vivonics Inc.
• Original Assignee: Vivonics Inc.
• Inventors: Gilman, Vladimir Leo
• Primary Examiner(s): Riley, Jezia
• Application Number:
  US14/278,159
• Publication Number:
  US 20140343264A1
• Time in Patent Office: 1,181 Days
• Field of Search: 536 231, 536 266, 544 44
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/152 on a single-stranded target, e.g. fold-back TFOs
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/311 Phosphotriesters
• CPC Class Codes: C12N 2310/3517 Marker; Tag
• CPC Class Codes: C12N 2320/52 modulating the physical stability, e.g. GC-content

Abstract

The invention generally relates to isolated nucleic acid ligands that are neutral under physiological conditions.

Claims

1. A nucleic acid ligand comprising repeating units of Formula I:

2. The nucleic acid ligand according to claim 1, wherein the O-glycosylated biomolecule is selected from the group consisting of a fatty acid, a sugar, an amino sugar, an amino acid, and a sialic acid.

3. The nucleic acid ligand according to claim 1, wherein the nucleic acid ligand is single stranded.

4. The nucleic acid ligand according to claim 1, wherein the nucleic acid ligand is double stranded.

5. The nucleic acid ligand according to claim 1, wherein Nuc₁ is a deoxyribonucleic acid.

6. The nucleic acid ligand according to claim 1, wherein Nuc₁ is a ribonucleic acid.

7. The nucleic acid ligand according to claim 1, further comprising a detectable label.

8. The nucleic acid ligand according to claim 7, wherein the detectable label is an optically detectable label.

9. The nucleic acid ligand according to claim 8, wherein the optically detectable label is a fluorescent label.